Evaluation of<sup>177</sup>Lu-PSMA-617 SPECT/CT Quantitation as a Response Biomarker Within a Prospective<sup>177</sup>Lu-PSMA-617 and NOX66 Combination Trial (LuPIN)-Reference-Cited by-同舟云学术

Evaluation of¹⁷⁷Lu-PSMA-617 SPECT/CT Quantitation as a Response Biomarker Within a Prospective¹⁷⁷Lu-PSMA-617 and NOX66 Combination Trial (LuPIN)

Published:2022-08-25 Issue:2 Volume:64 Page:221-226
ISSN:0161-5505
Container-title:Journal of Nuclear Medicine
language:en
Short-container-title:J Nucl Med

Author:

Pathmanandavel Sarennya,Crumbaker Megan,Ho Bao,Yam Andrew O.,Wilson Peter,Niman Remy,Ayers Maria,Sharma Shikha,Hickey Adam,Eu Peter,Stockler Martin,Martin Andrew J.,Joshua Anthony M.,Nguyen Andrew,Emmett Louise

Publisher

Society of Nuclear Medicine

Subject

Radiology, Nuclear Medicine and imaging

Reference30 articles.

1. Results of a Prospective Phase 2 Pilot Trial of 177Lu–PSMA-617 Therapy for Metastatic Castration-Resistant Prostate Cancer Including Imaging Predictors of Treatment Response and Patterns of Progression

2. [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial;Hofman;Lancet.,2021

3. Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer

4. Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of 177Lu-PSMA-617 Theranostics in Metastatic Castration-Resistant Prostate Cancer

5. Novel framework for treatment response evaluation using PSMA-PET/CT in patients with metastatic castration-resistant prostate cancer (RECIP 1.0): an international multicenter study

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of Posttreatment SPECT/CT on Patient Management During¹⁷⁷Lu-PSMA-617 Radiopharmaceutical Therapy;Journal of Nuclear Medicine;2024-08-08

2. [ ⁶⁸ Ga]PSMA-11 for positron emission tomography (PET) imaging of prostate-specific membrane antigen (PSMA)-positive lesions in men with prostate cancer;Expert Review of Molecular Diagnostics;2024-07-02

3. Treatment Response Imaging in Prostate Cancer;PET Clinics;2024-07

4. Same-day post-therapy imaging with a new generation whole-body digital SPECT/CT in assessing treatment response to [177Lu]Lu-PSMA-617 in metastatic castration-resistant prostate cancer;European Journal of Nuclear Medicine and Molecular Imaging;2024-04-18

5. Lutetium-177 radioisotope and therapeutic radiopharmaceuticals: Production, separation and purification, chelation labeling and clinical application;Chinese Science Bulletin;2024-04-12